O	0	6	Stress
O	7	17	management
O	17	18	,
O	19	28	leukocyte
O	29	44	transcriptional
O	45	52	changes
O	53	56	and
O	57	63	breast
O	64	70	cancer
O	71	81	recurrence
O	82	84	in
O	85	86	a
O	87	97	randomized
O	98	103	trial
O	103	104	:
O	105	107	An
O	108	119	exploratory
O	120	128	analysis
O	128	129	.

B-intervention	130	139	Cognitive
I-intervention	140	150	behavioral
I-intervention	151	157	stress
I-intervention	158	168	management
I-intervention	169	170	(
I-intervention	170	174	CBSM
I-intervention	174	175	)
O	176	178	is
O	179	181	an
O	182	193	empirically
O	193	194	-
O	194	203	validated
O	204	209	group
O	209	210	-
O	210	215	based
O	216	228	psychosocial
O	229	241	intervention
O	241	242	.

O	243	247	CBSM
O	248	250	is
O	251	258	related
O	259	261	to
O	262	271	decreased
O	272	276	self
O	276	277	-
O	277	285	reported
O	286	296	indicators
O	297	299	of
O	300	313	psychological
O	314	323	adversity
O	324	330	during
O	331	337	breast
O	338	344	cancer
O	345	354	treatment
O	355	358	and
O	359	366	greater
O	367	374	disease
O	374	375	-
O	375	379	free
O	380	388	survival
O	389	390	(
O	390	393	DFS
O	393	394	)
O	395	397	vs
O	397	398	.
O	399	400	a
O	401	408	control
O	409	418	condition
O	418	419	.

O	420	424	This
O	425	430	study
O	431	439	examined
O	440	453	relationships
O	454	461	between
O	462	466	CBSM
O	466	467	,
O	468	471	DFS
O	471	472	,
O	473	476	and
O	477	478	a
O	479	488	potential
O	489	502	biobehavioral
O	503	510	pathway
O	511	518	linking
O	519	524	these
O	525	534	variables
O	535	537	in
O	538	544	breast
O	545	551	cancer
O	552	560	patients
O	561	568	through
O	569	570	a
O	571	575	gene
O	576	586	expression
O	587	596	composite
O	597	609	representing
O	610	613	the
O	614	623	leukocyte
O	624	633	conserved
O	634	649	transcriptional
O	650	658	response
O	659	661	to
O	662	671	adversity
O	672	673	(
O	673	677	CTRA
O	677	678	)
O	678	679	.

B-eligibility	680	685	Women
I-eligibility	686	690	with
I-eligibility	691	696	stage
I-eligibility	697	698	0
I-eligibility	698	699	-
I-eligibility	699	703	IIIb
I-eligibility	704	710	breast
I-eligibility	711	717	cancer
O	718	727	completed
O	728	742	questionnaires
O	743	746	and
O	747	755	provided
O	756	761	blood
O	762	769	samples
O	770	774	post
O	774	775	-
O	775	782	surgery
O	782	783	.

O	784	796	Participants
O	797	801	were
O	802	812	randomized
O	813	815	to
O	816	818	10
O	818	819	-
O	819	823	week
O	824	829	group
O	829	830	-
O	830	835	based
O	836	840	CBSM
O	841	843	or
O	844	845	a
B-control	846	861	psychoeducation
I-control	862	869	control
I-control	870	875	group
O	876	879	and
O	880	888	followed
O	889	891	at
O	892	893	6
O	894	900	months
O	900	901	,
O	902	904	12
O	905	911	months
O	911	912	,
O	913	916	and
O	917	923	median
O	924	926	11
O	927	932	years
O	932	933	.

O	934	936	In
O	937	942	total
O	942	943	,
B-total-participants	944	946	51
O	947	959	participants
O	960	968	provided
O	969	974	blood
O	975	979	data
O	980	983	for
O	984	996	longitudinal
O	997	1005	analyses
O	1006	1007	(
O	1007	1011	CBSM
O	1012	1013	n
O	1013	1014	=
B-intervention-participants	1014	1016	28
O	1016	1017	;
O	1018	1025	Control
O	1026	1027	n
O	1027	1028	=
B-control-participants	1028	1030	23
O	1030	1031	)
O	1031	1032	.

O	1033	1038	Mixed
O	1039	1044	model
O	1045	1053	analyses
O	1054	1062	examined
O	1063	1067	CBSM
O	1068	1075	effects
O	1076	1078	on
O	1079	1080	6
O	1080	1081	-
O	1081	1083	12
O	1084	1089	month
O	1090	1097	changes
O	1098	1100	in
O	1101	1105	CTRA
O	1106	1116	expression
O	1117	1118	(
O	1118	1120	53
O	1121	1130	indicator
O	1131	1136	genes
O	1137	1149	representing
O	1150	1153	pro
O	1153	1154	-
O	1154	1166	inflammatory
O	1166	1167	,
O	1168	1172	anti
O	1172	1173	-
O	1173	1178	viral
O	1179	1182	and
O	1183	1191	antibody
O	1192	1202	production
O	1203	1212	signaling
O	1212	1213	)
O	1213	1214	.

O	1215	1218	Cox
O	1219	1229	regression
O	1230	1236	models
O	1237	1245	assessed
O	1246	1249	the
O	1250	1262	relationship
O	1263	1270	between
O	1271	1272	6
O	1273	1276	and
O	1277	1279	12
O	1280	1285	month
O	1286	1293	changes
O	1294	1296	in
O	1297	1301	CTRA
O	1302	1312	expression
O	1313	1316	and
O	1317	1319	11
O	1319	1320	-
O	1320	1324	year
O	1325	1328	DFS
O	1328	1329	.

O	1330	1338	Patients
O	1339	1349	randomized
O	1350	1352	to
O	1353	1357	CBSM
O	1358	1364	showed
O	1365	1375	attenuated
B-outcome	1376	1377	6
I-outcome	1377	1378	-
I-outcome	1378	1380	12
I-outcome	1381	1386	month
I-outcome	1387	1393	change
I-outcome	1394	1396	in
I-outcome	1397	1401	CTRA
I-outcome	1402	1406	gene
I-outcome	1407	1417	expression
O	1417	1418	,
O	1419	1426	whereas
O	1427	1435	patients
O	1436	1446	randomized
O	1447	1449	to
O	1450	1457	control
O	1458	1464	showed
O	1465	1474	increased
O	1475	1479	CTRA
O	1480	1490	expression
O	1491	1492	(
O	1492	1493	p
O	1493	1494	=
O	1494	1495	0
O	1495	1496	.
O	1496	1499	014
O	1499	1500	)
O	1500	1501	.

B-outcome	1502	1509	Average
I-outcome	1510	1513	DFS
O	1514	1517	was
O	1518	1519	5
O	1519	1520	.
O	1520	1522	92
O	1523	1528	years
O	1529	1530	(
O	1530	1532	SD
O	1532	1533	=
O	1533	1534	3
O	1534	1535	.
O	1535	1537	90
O	1537	1538	)
O	1538	1539	.

O	1540	1547	Greater
O	1548	1549	6
O	1549	1550	-
O	1550	1552	12
O	1553	1558	month
B-outcome	1559	1563	CTRA
O	1564	1573	increases
O	1574	1583	predicted
O	1584	1591	shorter
O	1592	1594	11
O	1594	1595	-
O	1595	1599	year
O	1600	1603	DFS
O	1604	1615	controlling
O	1616	1619	for
O	1620	1630	covariates
O	1631	1632	(
O	1632	1633	p
O	1633	1634	=
O	1634	1635	0
O	1635	1636	.
O	1636	1639	007
O	1639	1640	)
O	1640	1641	.

O	1642	1646	CBSM
O	1647	1657	attenuated
O	1658	1662	CTRA
O	1663	1667	gene
O	1668	1678	expression
O	1679	1685	during
O	1686	1689	the
O	1690	1697	initial
O	1698	1702	year
O	1703	1705	of
O	1706	1712	breast
O	1713	1719	cancer
O	1720	1729	treatment
O	1729	1730	.

O	1731	1733	In
O	1734	1738	turn
O	1738	1739	,
O	1740	1747	greater
O	1748	1757	increases
O	1758	1760	in
O	1761	1765	CTRA
O	1766	1770	gene
O	1771	1781	expression
O	1782	1791	predicted
O	1792	1799	shorter
B-outcome	1800	1804	long
I-outcome	1804	1805	-
I-outcome	1805	1809	term
I-outcome	1810	1813	DFS
O	1813	1814	.

O	1815	1820	These
O	1821	1829	findings
O	1830	1838	identify
O	1839	1840	a
O	1841	1854	biobehavioral
O	1855	1863	oncology
O	1864	1871	pathway
O	1872	1874	to
O	1875	1882	examine
O	1883	1885	in
O	1886	1892	future
O	1893	1897	work
O	1897	1898	.
